L ohp

Manufactured by Merck Group

Sourced in United States

The L-OHP is a laboratory equipment designed for optical heating and processing applications. It functions as a heating source, providing a controlled and uniform thermal environment for various scientific experiments and sample preparation procedures.

Automatically generated - may contain errors

Lab products found in correlation

Crystal violet, by Merck Group (1 mentions) Hct116, by American Type Culture Collection (1 mentions) Sw480, by American Type Culture Collection (1 mentions) Annexin 5, by BD (1 mentions) Leucovorin lv, by Merck Group (1 mentions) Dulbecco s modified eagle s medium, by Thermo Fisher Scientific (1 mentions) Multiskan mk3, by Thermo Fisher Scientific (1 mentions) Mtt assay, by Keygen Biotech (1 mentions) Inhibitor nc, by Thermo Fisher Scientific (1 mentions) Si nc, by Thermo Fisher Scientific (1 mentions) Lipofectamine 3000 reagent, by Thermo Fisher Scientific (1 mentions) Mimics nc, by Thermo Fisher Scientific (1 mentions) Ov nc, by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

Oxaliplatin (L-OHP)

7 protocols using l ohp

Evaluating Cell Viability and Clonogenicity

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell viability was assessed using the Cell Counting Kit-8 (CCK8) assay (Dojindo Laboratory, Japan) according to the manufacturer’s protocol. For the L-OHP and 5-FU viability assays, 5000 cells/well were seeded in 96-well plates, and then L-OHP (5 μmol/L) or 5-FU (10 μmol/L) was added (Sigma). Viability was measured after treatment with L-OHP or 5-FU for 48 h.
For the colony formation assay, cells were seeded in 12-well plates and then treated with 5 μmol/L L-OHP. After 2 h, the cells were harvested using trypsin, collected, and reseeded at a density of 2000 cells/well in 12-well plates. Then, the colonies were fixed and stained with 0.1% crystal violet (Sigma) 14 days later.

Shi T., Ma Y., Cao L., Zhan S., Xu Y., Fu F., Liu C., Zhang G., Wang Z., Wang R., Lu H., Lu B., Chen W, & Zhang X. (2019). B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death & Disease, 10(4), 308.

+ Open protocol

+ Expand

Colon Cancer Cell Lines Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human colon cancer cell lines HCT116 and SW480 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in DMEM supplemented with 10% FBS, and antibiotics (penicillin and streptomycin) were added at the temperature of 37°C with 5% CO₂. The cell culture reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Chloroquine (CQ), 3-methyladenine (3-MA), and L-OHP were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Annexin-V and propidium iodide (PI) dyes were purchased from BD Biosciences (San Jose, CA, USA). The specific siRNAs for KCNQ1OT1 and Atg4B and negative control were synthesized and purchased from Genecopoeia (Guangzhou, China). The miR-34a mimic, inhibitor, and their negative controls were synthesized and purchased from Gene Pharma (Shanghai, China).

Li Y., Li C., Li D., Yang L., Jin J, & Zhang B. (2019). lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway. OncoTargets and therapy, 12, 2649-2660.

+ Open protocol

+ Expand

Synergistic Effects of FOLFOX Chemotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

L-OHP, 5-FU, and leucovorin (LV) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions of these drugs were prepared in sterile distilled water with filtration. We chose concentrations of these drugs that caused 80%–90% growth reduction when used alone for HCT116 cell line: 2.5 µM of L-OHP, 25 µM of 5-FU, and 25 µM of LV. Cells were exposed to FL regimen (5-FU/LV) or folfox regimen (L-OHP/5-FU/LV) at 18 hours after transfection.

Oh B.Y., Kim K.H., Chung S.S, & Lee R.A. (2016). Silencing the livin gene enhances the cytotoxic effects of anticancer drugs on colon cancer cells. Annals of Surgical Treatment and Research, 91(6), 273-277.

+ Open protocol

+ Expand

Culturing Human Colorectal Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human colorectal cancer cell lines used in this study (HT29-D4, Caco-2, and RKO) were growth in DMEM medium (Dulbecco’s modified Eagle’s medium, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (fetal bovine serum) and L-glutamine (2 mM). Non-essential amino-acids were also added to the medium used to maintain Caco-2 cells. The cells were incubated at 37 °C in a humidified atmosphere with 5% CO₂. The HT29-D4 cells were originally selected from HT29 colon adenocarcinoma cells by Fantini et al. [15 (link)]. The oxaliplatin-resistant cells (Rox) were selected as described in our previous work [10 (link)]. These cells were cultured in the same medium as their parental cells, supplemented with 2 μM oxaliplatin (LOHP, Sigma-Aldrich, Merck, Darmstadt, Germany).

Chocry M., Leloup L., Parat F., Messé M., Pagano A, & Kovacic H. (2022). Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer. Cancers, 14(23), 5894.

+ Open protocol

+ Expand

Evaluation of Chemical Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

L-OHP and the other compounds were acquired from Sigma-Aldrich Company Ltd. (Milan, Italy). All other chemicals were of the highest viable grade available. All stock solutions were arranged in nonpyrogenic saline (0.9% NaCl; Baxter, Milan, Italy). PEA and PEA-OXA were provided by the Epitech Group (Saccolongo, Padua, Italy).

Campolo M., Lanza M., Paterniti I., Filippone A., Ardizzone A., Casili G., Scuderi S.A., Puglisi C., Mare M., Memeo L., Cuzzocrea S, & Esposito E. (2021). PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-κB/Nrf-2 Axis. International Journal of Molecular Sciences, 22(8), 3927.

+ Open protocol

+ Expand

Evaluating Anticancer Drug Efficacy with RAI2 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

LoVo/HCT116 cells were treated with a concentration gradient of anticancer drugs before and following re-expression of RAI2. The anticancer drugs, oxaliplatin (L−OHP) (Sigma, Beijing, China) and 5−fluorouracil (5−FU) (Princeton, NJ, USA) were tested in six dilutions respectively. The concentrations of L−OHP for treatment were 0.00, 1.00, 2.00, 4.00, 8.00, 16.00μM in LoVo/HCT116 cells and 0.00, 2.00, 4.00, 8.00, 16.00, 32.00μM in SW620 cells. The concentration of 5−FU for treatment was 0.00, 6.25, 12.50, 25.00, 50.00, 100.00μM in LoVo/HCT116/SW620 cells. The cells were seeded at a density of 3x10⁴ cells/well on 96−well plates in RPMI−1640 medium, each well was repeated in triplicate. The following incubation overnight at 37˚C, the medium growth was replaced by a fresh medium containing the test drug. All the cells were treated for 48 h. At the end of the treatment, cell viability was measured by the MTT assay (KeyGEN Biotech, Nanjing, China). Absorbance was measured on a microplate reader (Thermo Multiskan MK3, MA, USA) at a wavelength of 490 nm. IC50 was defined as the concentration of L-OHP/5-FU for 50% inhibition of cell growth. Each experiment was repeated three times.

Zhang W., Kong L., Zhu H., Sun D., Han Q., Yan B., Cui Z., Zhang W., Zhang S., Kang X., Dai G., Qian N, & Yan W. (2022). Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer. Frontiers in Oncology, 12, 805290.

+ Open protocol

+ Expand

Exploring L-OHP Sensitivity in HeLa Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

After preparing cell suspensions, we added 5, 10, 15, 20, 25, and 30 µM concentrations of L-OHP (Sigma-Aldrich, San Francisco, CA, USA) cell medium. Cells were treated with L-OHP for 48 hours and changed into fresh medium. Hela/L-OHP cells were cultured with the 50% maximal inhibitory concentration (IC50) of transfected cells against L-OHP for 3 hours to assess the chemical sensitivity of the drug. After treatment with drug, cells were subjected to further experiments. miR-34a-5p mimics, mimics-NC, miR-34a-5p inhibitor, and inhibitor-NC were purchased from Taitool Bioscience (Shanghai, China). si-NC, si-MDM4, ov-NC, and ov-MDM4 were designed and synthesized by Bio-Rad (Hercules, CA, USA). Then, Hela/L-OHP cells were transfected with miR-34a-5p mimics, mimics-NC, miR-34a-5p inhibitor, inhibitor-NC, si-NC, si-MDM4, ov-NC, and ov-MDM4 by using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA) as per instructions.

He P.T., Liu X., Lou Y., Gong S., & Cao L. (2022). miR-34a-5p enhances the sensitivity of cervical cancer cells to oxaliplatin chemotherapy via targeting MDM4. Clinical and Experimental Obstetrics & Gynecology, 49(2), 054-054.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!